Full text biomedical articles

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Maria Luisa Aznar, Theodore K. Marras, Ahmed Said Elshal, Mahtab Mehrabi, Sarah K. Brode
BMC Pharmacol Toxicol. 2019; 20: 37. Published online 2019 Jun 3. doi: 10.1186/s40360-019-0302-1


Article   |   PubReader   |   PDF–602K   |   Cite

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats

Vladimir Malinin, Mary Neville, Gina Eagle, Renu Gupta, Walter R. Perkins
Antimicrob Agents Chemother. 2016 Nov; 60(11): 6540–6549. Prepublished online 2016 Aug 22. Published online 2016 Oct 21. doi: 10.1128/AAC.00700-16


Article   |   PubReader   |   PDF–1.5M   |   Cite

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen

Hideo Kato, Mao Hagihara, Jun Hirai, Daisuke Sakanashi, Hiroyuki Suematsu, Naoya Nishiyama, Yusuke Koizumi, Yuka Yamagishi, Katsuhiko Matsuura, Hiroshige Mikamo
Drugs R D. 2017 Mar; 17(1): 177–187. Published online 2017 Jan 6. doi: 10.1007/s40268-016-0165-5


Article   |   PubReader   |   PDF–818K   |   Cite

Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the whiB7 Gene

Mark Pryjma, Ján Burian, Kevin Kuchinski, Charles J. Thompson
Antimicrob Agents Chemother. 2017 Nov; 61(11): e01353-17. Prepublished online 2017 Sep 5. Published online 2017 Oct 24. doi: 10.1128/AAC.01353-17


Article   |   PubReader   |   PDF–583K   |   Cite

Amikacin: Uses, Resistance, and Prospects for Inhibition

Maria S. Ramirez, Marcelo E. Tolmasky
Molecules. 2017 Dec; 22(12): 2267. Published online 2017 Dec 19. doi: 10.3390/molecules22122267


Article   |   PubReader   |   PDF–2.3M   |   Cite

Potentiation Effects of Amikacin and Fosfomycin against Selected Amikacin-Nonsusceptible Gram-Negative Respiratory Tract Pathogens

A. Bruce Montgomery, Paul R. Rhomberg, Tammy Abuan, Kathie-Anne Walters, Robert K. Flamm
Antimicrob Agents Chemother. 2014 Jul; 58(7): 3714–3719. doi: 10.1128/AAC.02780-13


Article   |   PubReader   |   PDF–1.2M   |   Cite

Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa

Maytham Hussein, Mei-Ling Han, Yan Zhu, Qi Zhou, Yu-Wei Lin, Robert E. W. Hancock, Daniel Hoyer, Darren J. Creek, Jian Li, Tony Velkov
Antimicrob Agents Chemother. 2020 Jan; 64(1): e01587-19. Prepublished online 2019 Oct 14. Published online 2019 Dec 20. doi: 10.1128/AAC.01587-19


Article   |   PubReader   |   PDF–3.5M   |   Cite

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use

Sheridan M. Hoy
Clin Drug Investig. 2021; 41(4): 405–412. Published online 2021 Mar 16. doi: 10.1007/s40261-021-01010-z


Article   |   PubReader   |   PDF–882K   |   Cite

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)

Natasha F. Sabur, Mantaj S. Brar, Lisa Wu, Sarah K. Brode
BMC Infect Dis. 2021; 21: 254. Published online 2021 Mar 10. doi: 10.1186/s12879-021-05947-6


Article   |   PubReader   |   PDF–537K   |   Cite

Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation

Cyril Touchard, Alexandra Aubry, Philippine Eloy, Nicolas Bréchot, Guillaume Lebreton, Guillaume Franchineau, Sebastien Besset, Guillaume Hékimian, Ania Nieszkowska, Pascal Leprince, Charles-Edouard Luyt, Alain Combes, Matthieu Schmidt
Crit Care. 2018; 22: 199. Published online 2018 Aug 19. doi: 10.1186/s13054-018-2122-x


Article   |   PubReader   |   PDF–1.1M   |   Cite

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease

Matt Shirley
Drugs. 2019; 79(5): 555–562. Published online 2019 Mar 15. doi: 10.1007/s40265-019-01095-z


Article   |   PubReader   |   PDF–987K   |   Cite

Amikacin-Fosfomycin at a Five-to-Two Ratio: Characterization of Mutation Rates in Microbial Strains Causing Ventilator-Associated Pneumonia and Interactions with Commonly Used Antibiotics

A. Bruce Montgomery, Paul R. Rhomberg, Tammy Abuan, Kathie-Anne Walters, Robert K. Flamm
Antimicrob Agents Chemother. 2014 Jul; 58(7): 3708–3713. doi: 10.1128/AAC.02779-13


Article   |   PubReader   |   PDF–154K   |   Cite

Resensitization of Fluconazole-Resistant Urinary Candida spp. Isolates by Amikacin through Downregulation of Efflux Pump Genes

EVA A. EDWARD, NELLY M. MOHAMED, AZZA S. ZAKARIA
Pol J Microbiol. 2020 Mar; 69(1): 73–84. Published online 2020 Mar 11. doi: 10.33073/pjm-2020-010


Article   |   PubReader   |   PDF–905K   |   Cite

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis

Shashikant Srivastava, Chawanga Modongo, Chandima W. Siyambalapitiyage Dona, Jotam G. Pasipanodya, Devyani Deshpande, Tawanda Gumbo
Antimicrob Agents Chemother. 2016 Oct; 60(10): 5922–5927. Prepublished online 2016 Jul 25. Published online 2016 Sep 23. doi: 10.1128/AAC.00961-16


Article   |   PubReader   |   PDF–630K   |   Cite

Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions

Norma A. Aréchiga-Alvarado, Susanna E. Medellín-Garibay, Rosa del C. Milán-Segovia, Arturo Ortiz-Álvarez, Martín Magaña-Aquino, Silvia Romano-Moreno
Antimicrob Agents Chemother. 2020 May; 64(5): e02178-19. Prepublished online 2020 Feb 10. Published online 2020 Apr 21. doi: 10.1128/AAC.02178-19


Article   |   PubReader   |   PDF–736K   |   Cite

Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

Clément Boidin, Laurent Bourguignon, Sabine Cohen, Claire Roger, Jean-Yves Lefrant, Jason A. Roberts, Bernard Allaouchiche, Alain Lepape, Arnaud Friggeri, Sylvain Goutelle
Antimicrob Agents Chemother. 2019 Nov; 63(11): e00993-19. Prepublished online 2019 Sep 3. Published online 2019 Oct 22. doi: 10.1128/AAC.00993-19


Article   |   PubReader   |   PDF–968K   |   Cite

Pharmacokinetics of regional limb perfusion using a combination of amikacin and penicillin in standing horses

Roee Dahan, Gil L. Oreff, Amos J. Tatz, Tal Raz, Malka Britzi, Gal Kelmer
Can Vet J. 2019 Mar; 60(3): 294–299.


Article   |   PubReader   |   PDF–737K   |   Cite

A robust LC–MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies

Katrina Chan, Weiqun Wang, Kimberly R Ledesma, Taijun Yin, Vincent H Tam
Bioanalysis. 2020 Apr; 12(7): 445–454. Published online 2020 Apr 28. doi: 10.4155/bio-2020-0007


Article   |   PubReader   |   PDF–484K   |   Cite

Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model

Beatriz E. Ferro, Shashikant Srivastava, Devyani Deshpande, Carleton M. Sherman, Jotam G. Pasipanodya, Dick van Soolingen, Johan W. Mouton, Jakko van Ingen, Tawanda Gumbo
Antimicrob Agents Chemother. 2016 Mar; 60(3): 1242–1248. Prepublished online 2015 Dec 7. Published online 2016 Feb 26. doi: 10.1128/AAC.02282-15


Article   |   PubReader   |   PDF–1.3M   |   Cite

Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy

Cédric Carrié, Faustine Delzor, Stéphanie Roure, Vincent Dubuisson, Laurent Petit, Mathieu Molimard, Dominique Breilh, Matthieu Biais
Antimicrob Agents Chemother. 2020 Apr; 64(4): e02098-19. Prepublished online 2020 Jan 21. Published online 2020 Mar 24. doi: 10.1128/AAC.02098-19


Article   |   PubReader   |   PDF–734K   |   Cite